in Newswire May 3, 2019

Class Action: Combivent Respimat Asthma Inhaler Contains Far Fewer Doses Than Advertised

by Corrado Rizzi

Last Updated on May 3, 2019

Ignacuinos v. Boehringer Ingelheim Pharmaceuticals, Inc.

Filed: May 3, 2019 § 3:19-cv-00672

A COPD sufferer alleges Boehringer Ingelheim's Combivent Respimat asthma inhaler contains far fewer than the 120 doses promised in the advertising and marketing of the treatment.




Last Updated on May 3, 2019 — 4:05 PM

Corrado Rizzi

Corrado Rizzi is the News Editor and a writer for

About is a group of online professionals (designers, developers and writers) with years of experience in the legal industry.

Learn More

Before commenting, please review our comment policy.